AXIN1 and hepatocellular carcinoma: The heterogeneity of HCCs has been extensively investigated, particularly focusing on genetic background as an HCC risk factor [25] Potential therapeutic targets in HCC, such as β-catenin, tumour protein p53, and axin 1 were identified by Schulze et al. [10].